Stifel lowered the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $48 and keeps a Buy rating on the shares. The firm has modeled a slower franchise ramp and reallocated share between Veligrotug and Elegrobart across active and chronic thyroid eye disease, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Raises $359 Million in Offerings
- Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
- Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
- Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
- Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook